Replimune (REPL) Group announced that the first patients have been enrolled in studies evaluating RP2 in two different settings: checkpoint naive metastatic uveal melanoma; and second-line recurrent or metastatic hepatocellular carcinoma. “On the heels of our BLA submission for RP1 and designation as breakthrough therapy, we are pleased that the first patients have been enrolled in both the RP2 HCC clinical trial and the registration intended study of RP2 in metastatic uveal melanoma,” said Sushil Patel, Ph.D., CEO of Replimune. “We are excited to explore the broader potential of the RPx platform and these RP2 clinical trials will play an important part of our future development plans.”
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REPL:
- Replimune management to meet with Jefferies
- Replimune price target raised to $19 from $16 at Jefferies
- Replimune 6.923M share Spot Secondary priced at $13.00
- Replimune announces proposed public offering of $125M of shares
- Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
